By Rahul Koul
“ There are inconstancies across biosimilar classes right now ”
Samsung Bioepis has just released their fourth quarter 2023 US Biosimilar Market Report , outlining the latest trends . In an exclusive interaction , Thomas Newcomer , VP , Head of US Market Access , Samsung Bioepis shares insightful perspectives on the findings
By Rahul Koul
BioTech
What are the key findings of your report and how do these predict the future of the US biosimilar market ?
Some key findings illustrated include details around the latest quarterly data points on biosimilar utilization and financial figures for the US Biosimilar market and the exploration of key determinants influencing various degrees of biosimilar utilization . By bringing the report out quarterly , we think there ' s tremendous value across payers , healthcare providers , any decision maker that ' s involved in the process .
We feel that if there is a more regular cadence with respect to delivering updated information , then stakeholders can see what ' s going on , not just in one biosimilar , or one therapeutic category , but across all of them . Everyone becomes better informed .
How do you look at the determinants influencing various degrees of biosimilar utilization despite 7 more adalimumab biosimilars launched in July 2023 ?
The first adalimumab biosimilar came to the market in January 2023 and
BIOVOICENEWS . COM 57